Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
Intra-Cellular Therapies (ITCI) PT More Than Doubled at Cowen
August 6, 2015 8:14 AM EDTCowen analyst Ritu Baral sharply raised the price target on Outperform-rated Intra-Cellular Therapies (NASDAQ: ITCI) to $62.00 (from $29.00) ahead of the '007 Ph3 read-out.
The firm has increased conviction around the clinical success of the program. "We look forward for the first Ph3... More
